Differential inhibitory and activating NK cell receptor levels and NK/NKT-like cell functionality in chronic and recovered stages of chikungunya

Subrat Thanapati¹, Mohini A. Ganu², Anuradha S. Tripathy¹*

¹ Hepatitis Group, National Institute of Virology, Pune, Pashan, Pune, Maharashtra, India, ² Sanjeevan Hospital, Majage Nagar, Latur, Maharashtra, India

* anuradhastripathy@hotmail.com

Abstract

The role of natural killer (NK; CD3⁻CD56⁺)/NKT (CD3⁺CD56⁺)-like cells in chikungunya virus (CHIKV) disease progression/recovery remains unclear. Here, we investigated the expression profiles and function of NK and NKT-like cells from 35 chronic chikungunya patients, 30 recovered individuals, and 69 controls. Percentage of NKT-like cells was low in chronic chikungunya patients. NKp30⁺, CD244⁺, DNAM-1⁺, and NKG2D⁺ NK cell percentages were also lower (MFI and/or percentage), while those of CD94⁺ and NKG2A⁺ NKT-like cells were higher (MFI and/or percentage) in chronic patients than in recovered subjects. IFN-γ and TNF-α expression on NKT-like cells was high in the chronic patients, while only IFN-γ expression on NK cells was high in the recovered individuals. Furthermore, percentage of perforin⁺ NK cells was low in the chronic patients. Lower cytotoxic activity was observed in the chronic patients than in the controls. CD107a expression on NK and NKT-like cells post anti-CD94/anti-NKG2A blocking was comparable among the patients and controls. Upregulated inhibitory and downregulated activating NK receptor expressions on NK/NKT-like cells, lower perforin⁺ and CD107a⁺NK cells are likely responsible for inhibiting the NK and NKT-like cell function in the chronic stage of chikungunya. Therefore, deregulation of NKR expression might underlie CHIKV-induced chronicity.

Introduction

The chikungunya virus (CHIKV) is a positive-sense, single-stranded RNA virus of the Alphavirus genus belonging to the family Togaviridae [1]. CHIKV belongs to the arthritogenic group of alphaviruses transmitted through the Aedes group of mosquitoes [2–4]. Re-emergence of chikungunya, with higher medical complications, since 2006 in several Asian and African countries, is a significant public health concern. Chikungunya outbreaks have been reported in America and the Caribbean Islands in late 2013 [5, 6]. Although chikungunya is a self-limiting disease usually resolved in acute stage, persistent joints pain lasts for several months or even years in 10–20% of patients after the initial infection [3, 7–11].
CHIKV-induced rheumatism (polyarthritis and/or polyarthritis) is a hallmark of chronic chikungunya, which deteriorates the patient’s quality of life [12]. The chronic polyarthritis is mostly symmetrical and involves small and large joints of the hands and feet, mimicking rheumatoid arthritis (RA) [11]. Persistent joint pain is a common symptom also caused by other CHIKV-related alphaviruses such as the Sindbis (SINV), Ross River (RRV), O’nyong-nyong, and Mayaro viruses [10]. A higher percentage of CHIKV-infected individuals suffer from chronic arthralgia and chronic CHIKV disease, tending to severe economic loss as reported previously [8, 12, 13–16]. Chronic and incapacitating arthralgia and subsequent injury to the joints are believed to occur because of viral and host immune-mediated effects. The precise role of different immune mediators in CHIKV-induced pathogenesis is less documented [17, 18].

Inefficient antiviral response of the host due to perturbation in its immune cell (natural killer [NK] cell, T cell, B cell etc.) functions could be a possible reason for virus persistence and/or chronic arthralgia. NK cells play an important role in the innate immune response whereas CD3⁺CD56⁺ NKT-like cells possess both innate and adaptive immune functions, with share characteristics of both T and NK cells. Both NK and NKT-like cells are essential in the host’s first line defense against viral infections and can produce antiviral effector cytokines including IFN-γ and TNF-α upon activation [19, 20]. NK/NKT-like cell function is regulated by differential engagement of NK cell surface receptors (NKRs), which are divided into activation (NKp30, NKp44, NKp46, NKG2D, and NKG2C) and inhibitory (CD158a, CD158b, KIR3DL1, CD94 and NKG2A) NKRs [21–24]. Subsets of NK and NKT-like cells are reported to be potent cytotoxic effector cells and producers of IFN-γ against hepatitis B virus (HBV) and contribute towards liver pathology during chronic HBV infection [25]. Roles of NK cells in alphavirus infections are reported to be both protective and pathogenic [26–28]. Further, a mouse model study has shown that persistent CHIKV infection causes chronic musculoskeletal tissue pathology, which is controlled by adaptive immune responses [29]. Studies from our group and others have reported that NK (CD3⁻CD56⁺)/NKT(CD3⁺CD56⁺)-like cells mount an early and efficient response after chikungunya infection [30–32]. However, literature on NK/NKT-like cells in CHIKV disease progression/recovery is limited [9].

The current study examines the changes in peripheral NK and NKT-like cell phenotype and functional activity in a cross-sectional cohort consisting of chronic patients and individuals recovered from chikungunya.

**Material and methods**

**Study population**

This study was approved by the “Institutional Ethics Committee for Research on Humans” as per the guidelines of Indian Council of Medical Research, New Delhi. The methods were carried out in accordance with the approved guidelines. Furthermore, informed written consent was obtained from all the participants prior to inclusion in the study (guardians filled the consent form on the behalf of minor participants). One hundred thirty-four individuals from Maharashtra, India, comprising of 35 patients in the chronic stage of chikungunya (mean age: 39 years; range: 12–65; gender ratio [male: female]: 0.6), 30 individuals who recovered from the disease (mean age: 43 years; range: 18–73; gender ratio: 1.1), and 69 controls (mean age: 30 years; range: 22–50; gender ratio: 1.3) were enrolled in the current study (Table 1).

Inclusion criteria were (1) chronic chikungunya patients; chronic persistent inflammatory polyarthritis/arthralgias lasting for more than three months following an episode of acute febrile polyarthritis and positive for chikungunya IgM/IgG antibodies [33]. Exclusion criteria for this group were the presence of RA factor, anti-CCP antibody, ANA positivity and raised...
Impaired functionality of NK cells in chronic chikungunya

Flow cytometric analysis

NK/NKT-like cells and their receptors. Freshly drawn peripheral blood from the 134 individuals was stained with specific anti-human monoclonal antibodies as described previously [30, 34]. NK/NKT-like cells and expression of activation and inhibitory receptors were checked using the appropriate monoclonal antibodies following a previously described staining protocol [30, 34]. Briefly, monoclonal antibodies specific for CD56 (clone B159), CD3 (clone SK7/UCHT1), NKp30/NKp44/NKp46/CD244/CD161/NKG2D/DNAM-1 (clone p30-15/p44-8/9E2/2-69/DX12/1D11/DX11) (BD Biosciences, CA, USA), CD94 (clone 131412) and NKG2A (clone 131411) (R and D Systems Inc., MN, USA) were used for phenotypic characterization of NK, NKT-like cells and NK receptors (NKR).

Cytotoxicity assay. Using a flow cytometry-based assay, NK/NKT-like cells activity was evaluated in 12 samples from each group following a previously reported method [30, 35]. Peripheral blood mononuclear cells (PBMCs) were isolated as per previously described protocol [34]. K562 cells (ATCC) served as the target and PBMCs as the effector. Briefly, K562 cells were labelled with carboxyfluoresceinsuccinimidyl ester (CFSE) (Molecular probes, Invitrogen, USA) (0.2 μM/10⁶ K562 cells). Subsequently, the labelled target cells were co-cultured with PBMCs at an effector to a target ratio of 10:1, and incubated for 6h at 37˚C. In order to assess the target cell lysis, co-cultured cells were kept on ice with 2 μg/ml 7-AAD (BD Biosciences, CA, USA) and incubated for 5 min for labelling the DNA of the dead cells. Unlabelled target cells alone served as the control. Percentage lysis was calculated using following formula:

\[
\% \text{specific killing} = \left( \frac{\% \text{experimental target death} - \% \text{spontaneous target death}}{100 - \% \text{spontaneous target death}} \right) \times 100.
\]

Degranulation assay. Degranulation activity quantitated based on anti-CD107a (Lamp1) expression was evaluated on the NK/NKT-like cells as reported previously [30, 33, 36]. Briefly, degranulation was induced by addition of K562 (target) into the well containing PBMCs (effector) at a effector: target:: 10:1 or phorbol 12-myristate 13-acetate (PMA) plus ionomycin and incubated at 37˚C. Culture medium (RPMI + 10% FBS) alone served as negative control, while PBMCs

Table 1. Characteristics of study population.

| Parameters               | Chronic | Recovered | Controls |
|--------------------------|---------|-----------|----------|
| Study population         | n = 35  | n = 30    | n = 69   |
| Gender ratio (Male: Female) | 0.6     | 1.1       | 1.3      |
| Age (years): mean (range) | 39 (12–65) | 43 (18–73) | 30 (22–50) |
| Post infection months: mean (range) | 86 (3–109) | 24 (3–36) | NA       |
| Anti-CHIKV IgM            | Positive/Negative | Negative | Negative |
| Anti-CHIKV IgG            | Positive | Positive  | Negative |

NA: Not applicable

https://doi.org/10.1371/journal.pone.0188342.t001
stimulated with PMA and ionomycin served as positive control. After 1 h of stimulation, 4µg/ml of brefeldin A (Sigma, MO, USA) and 5 µg/ml of monensin sodium salt (Sigma, MO, USA) were added and the cells were incubated for a total of 6 h followed by staining of the cells with antibodies against the cell surface antigen. To assess the role of NKG2A and CD94 towards the impairment of NK/NKT-like cells functions in the chronic chikungunya patients, PBMCs isolated from chronic chikungunya patients were incubated with neutralizing antibodies against NKG2A (clone 131411)/CD94 (clone 131412) (R and D Systems Inc., MN, USA) as per the manufacturer’s instruction before performing the degranulation assay. Briefly, PBMCs were incubated with NKG2A (1 µg/10⁶ cells) or CD94 (2.5 µg/10⁶ cells) neutralizing antibody for 30 min at room temperature. Following incubation, the unbound antibodies were washed with phosphate buffer saline, and the washed PBMCs were co-incubated with the K562 cells as described previously [30].

**Intracellular cytokines and perforin assay.** Intracellular cytokine staining and perforin assays were performed as described previously [30, 33, 35]. *In vitro* stimulation of effector cells with target cells and the incubation period were the same as described above. After incubation, cells were washed and stained with antibodies against CD56 (clone B159) and CD3 (clone SK7) (BD Biosciences, CA, USA). The surface-stained cells for NK/NKT-like cells were permeabilized using BD Cytofix/Cytoperm solution (BD Bioscience, CA, USA) and then subject to intracellular cytokine staining using IFN-γ (clone 25723.11)/TNF-α (clone MAb11)/perforin (clone δG9) (BD Bioscience, CA, USA) antibodies.

Acquisition and analysis of the samples were performed in the BD FACS ARIA II using FACS DIVA software (BD Biosciences, CA, USA).

**IFN-γ ELISPOT assay**

Chikungunya virus-specific IFN-γ release was studied using the ELISPOT assay as reported [30, 34]. Purification and inactivation of CHIKV were performed as previously described [37]. Briefly, the whole inactivated virus (10 µg/ml) was used for the enumeration of the virus-specific IFN-γ secreting spot. PBMCs stimulated with Phytohemagglutinin A (PHA) (10 µg/ml) (Sigma, MO, USA) and culture medium alone were used as stimuli for positive and negative controls, respectively. The IFN-γ spot-forming cells (SFCs) were counted in the ELISPOT reader (Carl Zeiss, Jena, Germany) using the KS ELISPOT software. The average number of SFCs in the negative control wells was set as cut-off level. Wells with a high background or without a PHA response were excluded. Number of SFCs in unstimulated wells was subtracted from the antigen-stimulated wells in each subject group for comparison.

**Software and statistical analysis**

A non-parametric Mann-Whitney U-test (where the difference in variances < 4) and Kolmogorov-Smirnov test (where the difference in variances > 4) were carried out for intergroup comparison using the SPSS 2.0 software (SPSS Inc., IL, USA). The validity of the comparison among each pair of groups was assessed using Kruskal-Wallis test before the Mann-Whitney U-test and Kolmogorov-Smirnov test. Data were expressed as mean (range). p values < 0.05 were considered statistically significant.

**Results**

**NK and NKT-like cell subsets in chronic and recovered stages of chikungunya**

In order to examine the phenotype of innate immune cells post acute chikungunya infection, percentages of NK and NKT-like cells were enumerated in the chronic patients and recovered
individuals by flow cytometry. The percentage of NKT-like cells was lower in chronic patients than in the controls and recovered individuals (chronic: mean, 3.1 [range, 0.9–15.5], vs. recovered: 5.1 [0.9–18.3], and vs. controls: 6.2 (0.1–26.1; \( p < 0.05 \) in each case) (Fig 1A). Absolute count of NKT-like cells was lower in the chronic patients than in the controls (chronic: 138

Fig 1. NK (CD3\(^{-}\)CD56\(^{+}\)) and NKT-like (CD3\(^{+}\)CD56\(^{+}\)) cells distribution during chikungunya. Percentages of the lymphocytes mentioned were determined from the whole blood of 35 chronic patients, 30 individuals recovered from chikungunya, and 69 controls. Box plots show the percentages of (A) NKT-like cells and (B) NK cells. Boxes represent interquartile ranges, vertical lines represent ranges and horizontal lines represent medians. Nonparametric Kolmogorov-Smirnov test was used for intergroup comparison. \( p \) value < 0.05 is considered significant. (C) Gating strategies used for NK, NKT-like and NK receptors\(^{+}\) (NKRs\(^{+}\)) NK/NKT-like cells were same as described earlier [30]. Lymphocytes are gated in FSC vs. SSC plot, upper left quadrant (Q1) of contour plot shows NK cells (CD3\(^{-}\)CD56\(^{+}\)) and upper right quadrant (Q2) shows NKT-like cells (CD56\(^{+}\)CD3\(^{+}\)). NK/NKT-like cells were gated within the lymphocytes as per CD56 and CD3 staining pattern and NKRs were gated on NK/NKT-like cells individually. The gate for NKR expression was set as per the expression in fluorescence minus one (FMO) cells. Histogram plots represent the percentage of NKRs\(^{+}\) (NK receptors) NK/NKT-like cells.

https://doi.org/10.1371/journal.pone.0188342.g001
Expression of NKRs on NK cells

Next, we investigated whether comparable percentages of NK cells have any influence on the expression of activation and inhibitory NKRs. Percentages of NKp30⁺, NKG2D⁺, CD244⁺, and DNAM-1⁺ NK cells were lower in chronic patients than in the recovered individuals (p < 0.05 in each case) (Table 2, Fig 2A, 2D, 2E and 2G). Except for CD244⁺, the mean fluorescence intensity (MFI) of NKp30⁺, NKG2D⁺, and DNAM-1⁺ NK cells were lower in the chronic patients than in the recovered individuals (Panels A, D, E, and G in S1 Fig). Lower percentages of NKp30⁺, NKp44⁺, and NKG2D⁺ NK cells were observed in the chronic and recovered groups than in the controls (p < 0.01 in each case) (Table 2, Fig 2A, 2B and 2D). On the other hand, percentages of NKp46⁺, CD244⁺, CD161⁺, and DNAM-1⁺ NK cells were low only in the chronic patients, compared with that in the controls (p < 0.05 in each case) (Table 2, Fig 2C, 2E, 2F and 2G). The MFI of DNAM-1⁺ NK cells was lower in chronic patients than in the controls (Panel G in S1 Fig).

Nevertheless, the percentage of NKG2A⁺ NK cells was higher in the chronic patients than in the controls (p = 0.019) while, CD94⁺ NK cells was comparable (Table 2, Fig 2H and 2I). The percentages of CD94⁺ and NKG2A⁺ NK cells were comparable among recovered and healthy controls.

Table 2. Percentage of NKR expression on NK/NKT-like cells.

| Types of NKRs          | NKR⁺ CD3⁺CD56⁺ cells | Control Mean (range) | Chronic Mean (range) | Recovered Mean (range) |
|------------------------|----------------------|----------------------|----------------------|------------------------|
| Activating NCRs        | Nkp30                | a52.4(4.9–87.8)      | 23.7(0–72.1)         | a38(9.3–92.3)           |
|                        | Nkp44                | a2.1(0–5.5)          | 0.9(0–8.3)           | 0.3(0–1.9)              |
|                        | Nkp46                | a66.4(2.2–98.1)      | 53.7(15.6–100)       | 61.9(29.1–93)           |
| Other cytotoxic receptors and co-receptors | NKG2D     | a83.7(9.5–100)       | 46.7(19.2–95.5)      | 56.8(37.9–80.6)         |
|                        | CD244                | a3(0.1–28.5)         | 1.3(0–7)             | a3(0–31.3)              |
|                        | CD161                | a57.9(9.6–88.4)      | 41.7(8.9–90.5)       | 49.5(13.5–82.6)         |
|                        | DNAM-1               | a18.9(1–46.2)        | 7.3(0–27.9)          | a23.4(3.6–68.4)         |
| Inhibitory             | CD94                 | 58.0(12.3–85.4)      | 63.9(23.5–100)       | 67.3(2.4–95)            |
|                        | NKG2A                | 20.4(3.5–51)         | a30.5(4.4–82.6)      | a27(0.1–72.5)           |

| Types of NKRs          | NKR⁺ CD3⁺CD56⁺ cells | Control Mean (range) | Chronic Mean (range) | Recovered Mean (range) |
|------------------------|----------------------|----------------------|----------------------|------------------------|
| Activating NCRs        | Nkp30                | a13.6(1.6–88.1)      | 8.8(0–59.6)          | 6.2(0–37.5)            |
|                        | Nkp44                | a13.8(1.6–33.1)      | 0.5(0–2.8)           | 0.6(0–8.3)             |
|                        | Nkp46                | a39.4(1.4–95.1)      | 4.9(39.7)            | 1.7(0–8.8)             |
| Other cytotoxic receptors and co-receptors | NKG2D     | a81.3(33.8–98.3)     | 40.5(12–80)          | 45.7(16.7–77.8)        |
|                        | CD244                | 0.5(0–3.3)           | 2.3(0–29.5)          | 1.9(0–22.6)            |
|                        | CD161                | 31.7(12.5–72.7)      | 31.8(6–72.7)         | 33.9(5.8–72.2)         |
|                        | DNAM-1               | a36.5(4.6–62.8)      | 19.5(0–45.3)         | a36.5(8.3–79.5)        |
| Inhibitory             | CD94                 | 23.9(5.8–50.6)       | a30.6(0–100)         | 19(0–58.3)             |
|                        | NKG2A                | 5.6(0.7–28.6)        | a19.8(0–100)         | 8.7(0–40.8)            |

* symbol shows the most frequent NKR in the respective group compared with either one or both of other studied groups mentioned on the table header.

NCRs: Natural cytotoxic receptors

https://doi.org/10.1371/journal.pone.0188342.t002
control groups (Table 2, Fig 2H and 2I). However, the MFI of CD94⁺ NK cells was higher in chronic than those in the recovered and control groups (Panel H in S1 Fig). The MFI of NKG2A⁺ NK cells was also higher in chronic patients than in the controls (Panel I in S1 Fig).

Expression of NKR3s on NKT-like cells

Next, we investigated the changes in activation and inhibitory NKR expression on NKT-like cells. Percentage of DNAM-1⁺ NKT-like cells was lower in the chronic patients than in the recovered individuals (p = 0.006) (Table 2, Fig 2P). Similarly, the MFI of DNAM-1⁺ NKT-like cells was also lower in chronic patients than in the recovered individuals (Panel P in S1 Fig). Lower percentages of NKp44⁺, NKp46⁺, and NKG2D⁺ NKT-like cells were observed in the chronic and recovered groups than in the controls (p < 0.0001 in each case) (Table 2, Fig 2K, 2L, and 2M). However, the MFI of only NKp46⁺ NKT-like cells was low in chronic and recovered groups than in the controls (Panel L in S1 Fig). On the other hand, the percentages of NKp30⁺ and DNAM-1⁺ NKT-like cells was low only in the chronic patients compared with that in the controls (p < 0.05 in each case) (Table 2, Fig 2K and 2L).

Higher percentages of CD94⁺ and NKG2A⁺ NKT-like cells were observed in the chronic patients than in the recovered individuals (p < 0.05 in each case). Percentage of NKG2A⁺ NKT-like cells was higher in the chronic and recovered groups than those in the controls (p < 0.05 in each case) while, CD94⁺ NKT cells in the control was comparable with chronic and recovered groups (Table 2, Fig 2Q and 2R). However, the MFI of CD94⁺ and NKG2A⁺ NKT-like cells were higher in chronic than in the recovered and control groups (Panels Q and R in S1 Fig).

Gating strategies adopted for enumeration of the NKR3s are described in Fig 1C.

Impaired functionality of NK and NKT-like cells in chronic chikungunya patients

Altered cytotoxicity. Since the expressions of NKR3s on NK/NKT-like cells were altered in the groups studied, we performed an effector/target cell-based assay to correlate these changes with NK/NKT-like cell functionality. A lower target-cell killing was observed in the chronic patients compared with that in the controls (% specific killing: chronic 0.3 [0–0.7] vs. controls 2 [0.4–3.7], p = 0.002) (Fig 3A). Cytotoxicity was comparable among the recovered and control groups.

Altered CD107a and perforin expression. An effector/target cell-based flow cytometry assay was carried out to assess the expression of CD107a and perforin on NK/NKT-like cells. The chronic chikungunya patients had lower expressions of CD107a and perforin on the NK cells compared with the controls (CD107a: chronic 0.7 [0–3.4] vs. controls 5.4 [0.2–9.7], p = 0.001); perforin: chronic 2.3 [0.8–3.4] vs. controls 21.3 [2.9–42], p < 0.0001) (Fig 3B and 3D, respectively). Similarly, the MFI of perforin⁺ NK cells was also lower in chronic patients than in the controls (Panel A in S2 Fig). The expression of these molecules was comparable among the recovered and control groups (Fig 3B–3E). Perforin⁺ NK cells were more abundant in the recovered individuals than in the chronic patients (perforin: chronic 2.3 [0.8–3.4] vs. recovered 18 [3.4–55.1], p < 0.0001) (Fig 3D). Similarly, the MFI of perforin⁺ NK cells was also higher in recovered individuals than in the chronic patients (Panel A in S2 Fig). The percentage and MFI of perforin⁺ NKT-like cells were comparable among the studied groups (Fig 3E, Panel B in S2 Fig).

To assess the impact of inhibitory NKR3s (CD94 and NKG2A) on NK/NKT-like cell function (CD107a expression), we performed another effector/target cell-based assay using neutralizing antibodies against CD94 and NKG2A in both chronic chikungunya patients and in
control individuals. Blocking these molecules resulted increased the CD107a expression on NK (CD107a+ NK cell: chronic 0.7 [0–3.4], control with anti-CD94 2.9 [1.3–4.8] vs. chronic with anti-CD94 9.1 [0–18.1], \( p < 0.05 \) in each case; chronic 0.7 [0–3.4], control with anti-NKG2A 1.6 [0.1–2.7] vs. chronic with anti-NKG2A 7.8 [0–15.6], \( p < 0.05 \)in each case) and NKT-like cells (CD107a+ NKT-like cell: chronic 2.3 [0–8.1], control with anti-CD94 0 [0] vs. chronic with anti-CD94 9.8 [0–19.5], \( p < 0.05 \) in each case; chronic 2.3 [0–8.1], control with anti-NKG2A 0 [0] vs. chronic with anti-NKG2A 12.3 [0–31.6], \( p < 0.05 \) in each case) in chronic patients (Fig 3F and 3G). CD107a expression on both NK and NKT-like cells post anti-CD94/anti-NKG2A blocking was comparable among the chronic patients and control individuals (Fig 3F and 3G).

IFN-\( \gamma \) and tumour necrosis factor (TNF)-\( \alpha \) expression on NK/NKT-like cells

To study the effector function (cytokine production) of NK/NKT-like cells post acute chikungunya infection, we performed intracellular cytokine staining for IFN-\( \gamma \) and TNF-\( \alpha \). Higher

---

**Fig 2. NK receptors (NKRs) expression on NK and NKT-like cells during chikungunya.** Frequencies of NKRs were enumerated from the whole blood of 35 chronic patients, 30 individuals recovered from chikungunya, and 69 controls. Box plots (A–I) show percentages of NKRs+ NK cells as (A) NKp30, (B) NKp44, (C) NKp46, (D) NKG2D, (E) CD244, (F) CD161, (G) DNAM-1, (H) CD94 and (I) NKG2A. Box plots (J–R) show percentages of NKRs+ NKT-like cells as (J) NKp30, (K) NKp44, (L) NKp46, (M) NKG2D, (N) CD244, (O) CD161, (P) DNAM-1, (Q) CD94, and (R) NKG2A. Kolmogorov-Smirnov-test was used for intergroup comparison. \( p \) value <0.05 is considered significant.

https://doi.org/10.1371/journal.pone.0188342.g002
IFN-γ expression was observed on the NK cells of the recovered individuals than in the NK cells of the chronic and control individuals (IFN-γ: recovered 2.1 [0.5–4.8] vs. chronic 1.1 [0–5.6], and vs. controls 0.3 [0–0.6], \( p < 0.05 \) in each case) (Fig 4A). However, IFN-γ expression on the NKT-like cells of chronic patients was higher than that in the controls (IFN-γ: chronic 6.2 [0.1–18.5] vs. controls 0.6 [0.1–1.8], \( p = 0.001 \)) (Fig 4B). NKT-like cells from the chronic patients showed higher TNF-α expression compared with the other subjects (TNF-α: chronic 11.3 [2.3–75], vs. recovered 2.1 [0–7.4], and vs. controls0.4 [0–1], \( p < 0.05 \) in each case) (Fig 4D). TNF-α expression in the NK cells was comparable among all the groups (Fig 4C). IFN-γ and TNF-α expressions in positive controls (phorbol-12-myristate-13-acetate + ionomycin,
stimulated) were [IFN-γ⁺ NK cells: controls 13.5 (10–16.2), chronic 16.3 (14.2–18.3), and recovered 14.8 (13.2–17.1); IFN-γ⁺ NKT-like cells: controls 21.2 (13.2–28.1), chronic 16.7 (14.4–19), and recovered 16.3 (11.8–2)] and TNF-α [TNF-α⁺ NK cells: controls 14.5 (8.7–20.3), chronic 17.6 (16.7–18.4), and recovered 11.7 (10.8–12.5); TNF-α⁺ NKT-like cells: controls 24.9 (17.8–32), chronic 15.5 (11.8–19.2), and recovered 17.8 (15.8–19.8)] comparable among chronic and recovered groups.

Reduced CHIKV-specific IFN-γ release in the chronic chikungunya patients

To determine the CHIKV-specific IFN-γ response, we performed an enzyme-linked immunospot (ELISPOT) assay using whole CHIKV particles as antigen. IFN-γ release in the negative control (medium-stimulated cells) was higher in the chronic patients than in the control and

Fig 4. Intracellular cytokines expression of NK/NKT-like cells during chikungunya against target cells (K562). PBMCs (effector) were isolated from the whole blood of 12 chronic patients, 12 individuals recovered from chikungunya, and 12 controls. PBMCs were co-cultured with K562 (target) cells at effector/target ratio of 10:1 for 6 h. Box plots show (A) IFN-γ by NK cells, (B) IFN-γ by NKT-like cells, (C) TNF-α by NK cells, and (D) TNF-α by NKT-like cells. Mann-Whitney U-test/Kolmogorov-Smirnov test was used for intergroup comparison. p value <0.05 is considered significant.

https://doi.org/10.1371/journal.pone.0188342.g004
recovered individuals (chronic 23 [0–91] vs. recovered 1 [0–8], and vs. controls 1 [0–6], p<0.05 in each case) (Fig 5A). In addition, CHIKV-specific IFN-γ release was higher in the individuals recovered from chikungunya compared with chronic patients and controls (recovered 14 [1–79] vs. chronic 1 [0–7], and vs. controls 1 [0–8], p<0.05 in each case) (Fig 5B). IFN-γ release in the positive controls (Phytohemagglutinin A [PHA]-stimulated cells) were 113 (25–248), 130(51–512), and 362(174–565) in the control, chronic, and recovered groups, respectively (Fig 5C).

**Discussion**

Having previously established the potential role of cytotoxic NK/NKT-like cells in influencing the pathogenesis of early CHIKV infection, here we attempted to understand the mechanisms...
that limit viral dissemination/establishment of chronicity in chikungunya disease. Immune effector cells, such as NK cells, have been implicated in the early control of various viral infections; hence, it was of interest to investigate the intrinsic association between deregulated NKR expression and lymphocyte function in both chronic patients and individuals recovered from chikungunya infection.

Impairment of NK cell function in the chronic patients, irrespective of NK cell percentage being comparable with the controls, may be a specific phenomenon indicating that the functional capacity per NK cell in the chronic chikungunya patients is low. Further, lower percentage of NKT-like cells in the chronic patients may be due to high turnover of NKT-like cells or due to their migration into the inflamed joints during chronic stage of chikungunya. Considering its substantial role in host’s antiviral defense, impact of lower percentage of NKT-like cells with the chronicity of CHIKV infection cannot be ruled out.

Our data showed that the expression of inhibitory receptors NKG2A and CD94 were high (MFI and/or percentage) on the NK/NKT-like cells of chronic chikungunya patients. This highlights a complex interplay between NK/NKT-like cell receptors and their function with the phase of the disease. Restoration of the function (degranulation capacity) of the NK/NKT-like cells in the chronic patients following blocking with anti-CD94 or anti-NKG2A antibodies suggest investigation of their role in chikungunya associated chronicity. NKG2A has been reported to be involved in cytotoxic T lymphocyte (CTL) regulation [23, 24]. Restoration of CTL in invitro-expanded, NKG2A-positive melanoma cells by blocking CD94/NKG2A with a specific antibody has also been described [23, 24, 38].

Lower expression of activation receptors on NK and/or NKT-like cells in the peripheral blood of chronic patients could be attributed to infiltration of activated NK/NKT-like cells into the synovial fluid as reported previously in chronic chikungunya patients [9]. Lower percentage of activation receptor-expression on NK/NKT-like cells in the chronic patients is reminiscent of reduced surface expression of Nkp30 and Nkp46 in HIV-1-infected patients, another chronic viral infection [39]. Furthermore, higher expression of activation receptors Nkp30, Nkp44, Nkp46, and CD244, and lower levels of inhibitory receptors NKG2A and CD94 on NK cells can deliver an effective cytotoxic response, as demonstrated previously [30, 39–41]. Downregulation of activation receptors may be a possible mechanism adopted by different viruses/viral antigens to counteract NK/NKT-like cell functions. Increased percentage of NKG2D+NK cells in the recovered individuals compared with the chronic patients indicates their potential role in the recovery from chikungunya.

Increased levels of inflammatory mediators such as MCP-1, TNF-α and IFN-γ have been reported in many viral arthritides [42, 43]. This is corroborated by the higher percentages of TNF-α- and IFN-γ-producing NKT-like cells in the chronic patients studied here. These results also indicate their possible involvement in CHIKV-induced arthritis. NK cells are one of the earliest effector cells to respond to viral infection, where they exert their effects through IFN-γ production [44]. It is noteworthy that our current and previously published data have shown increased IFN-γ expression on the NKT-like cells of patients at different phases of chikungunya infection [30]. In a mouse model of CHIKV arthritis, levels of IFN-γ and TNF-α were reported to be elevated and were associated with arthritic inflammation [45]. Furthermore, we have previously shown higher TNF-α+ and IFN-γ+ NKT-like T cells in both arthritic patient groups (chronic chikungunya arthritis and RA) [33]. Higher percentages of TNF-α- and IFN-γ-expression on NKT-like cells, irrespective of lower percentage of peripheral NKT-like cells in the chronic patients of the current study is consistent with the above report and indicates probable involvement of these mediators in chikungunya chronicity. However, further studies are needed to analyse the role of IFN-γ and TNF-α producing NKT-like cells in the chronic stage of chikungunya.
The secretion of IFN-γ is a major effector function of NK cells and may have direct as well as indirect anti-viral activities. IFN-γ production has been associated with recovery from Semiliki Forest virus (SFV) infection [46], while perforin has been shown to play a crucial role in the recovery of mice from some viral infections [47]. On similar lines, IFN-γ and perforin expression on NK cells of the current recovered individuals indicate crucial role of these molecules. Contribution of IFN-γ (released in ELISPOT) towards the development of an effective adaptive immune response in recovered individuals needs exploration.

The disease affects all age groups with female preponderance [11]. Similarly, current chronic patient group contained more female than male individuals. However, statistical analyses of each assay parameter following separation by gender were comparable to the pooled results, indicating that the data were not influenced by the gender ratio.

Upregulated inhibitory and downregulated activating NKR expression might hinder the cytolytic functions of NK and NKT-like cells in the chronic stage of chikungunya, indicating deregulation of NKR expression as one of the mechanisms for defective cellular response in CHIKV-induced chronicity. NKG2D and IFN-γ expression on NK cells and CHIKV-specific IFN-γ production in the recovered individuals, compared with that in chronic patients, indicates the role of NK and/or T cell effector function in recovery. Considering the outcomes of our previous [33] and current study, we can speculate that anti-TNF-α therapy could be a treatment strategy for chronic chikungunya patients. Overall, we have shown in this study that NK cells are dysfunctional in the periphery, and have suggested a pathogenic role of NKT-like cell subsets in chronic chikungunya patients. Future longitudinal studies are required to ascertain how the phenotypic NKR deregulation and functional changes in NK/NKT-like cells modulate the persistence of chronicity in chikungunya.

Supporting information

S1 Fig. Mean fluorescence intensity (MFI) of NKR⁺ NK/NKT-like cells. The box plots show the MFI of NKR⁺ NK cells in chronic chikungunya patients, recovered individuals, and controls. The figures (A–I) show the MFI of NKR⁺ NK cells as (A) NKp30, (B) NKp44, (C) NKp46, (D) NKG2D, (E) CD244, (F) CD161, (G) DNAM-1, (H) CD94 and (I) NKG2A. The figures (J–R) show the MFI of NKR⁺ NKT-like cells as (J) NKp30, (K) NKp44, (L) NKp46, (M) NKG2D, (N) CD244, (O) CD161, (P) DNAM-1, (Q) CD94, and (R) NKG2A. Mann–Whitney U-test/Kolmogorov-Smirnov-test was used for intergroup comparison. p value <0.05 is considered significant.

S2 Fig. MFI of perforin⁺ NK/NKT-like cells. The box plots show the MFI of perforin in chronic chikungunya patients, recovered individuals, and controls. The figures show (A) MFI of perforin⁺ NK cells and (B) MFI of perforin⁺ NKT-like cells. Kolmogorov-Smirnov-test was used for intergroup comparison. p value <0.05 is considered significant.

S1 Table. Mean fluorescence intensity of NKR⁺.

Acknowledgments

We thank Director, National Institute of Virology, for all the encouragement. Special thanks are due to Mr. Prasad Babar, Mr. Vasant Walkoli, Mr. Bipin Tilekar, Mr. Sarang Kamble, Mr. Dasharath, Mr. Prakash Sarje, Mr. Prakash B. Jawalkar, Ms. Neeta Thorat and Mr. Shirish Vaidya for technical help. We thank Ms. Shruti Kulkarni for her timely help. Mr. Subrat Thanapati
would like to thank the University Grant Commission, New Delhi, India for providing the Senior Research Fellowship.

**Author Contributions**

*Conceptualization:* Subrat Thanapati, Anuradha S. Tripathy.

*Data curation:* Subrat Thanapati, Mohini A. Ganu.

*Formal analysis:* Subrat Thanapati.

*Investigation:* Subrat Thanapati, Mohini A. Ganu, Anuradha S. Tripathy.

*Methodology:* Subrat Thanapati, Anuradha S. Tripathy.

*Resources:* Mohini A. Ganu, Anuradha S. Tripathy.

*Supervision:* Anuradha S. Tripathy.

*Validation:* Subrat Thanapati.

*Writing – original draft:* Subrat Thanapati.

*Writing – review & editing:* Mohini A. Ganu, Anuradha S. Tripathy.

**References**

1. Kennedy AC, Fleming J, Solomon L. Chikungunya viral arthropathy: a clinical description. J Rheumatol. 1980; 7: 231–6. PMID: 7373626

2. Renault P, Solot JL, Sissoko D, Balleydier E, Larrieu S, Filleul L, et al. A major epidemic of chikungunya virus infection on Reunion Island, France, 2005–2006. Am J Trop Med Hyg. 2007; 77: 727–31. PMID: 17978079

3. Pialoux G, Gauzeres BA, Jaureguiberry S, Strobel M. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis. 2007; 7: 319–27. https://doi.org/10.1016/S1473-3099(07)70107-X PMID: 17448935

4. Powers AM, Logue CH. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol. 2007; 88: 2363–77. https://doi.org/10.1099/vir.0.82858-0 PMID: 17698645

5. Leparc-Goffart I, Nougairede A, Cassadou S, Prat C, de Lamballerie X. Chikungunya in the Americas. Lancet. 2014; 383: 383–91. https://doi.org/10.1016/S0140-6736(14)60185-9 PMID: 24506907

6. Van Bortel W, Dorleans F, Rosine J, Blateau A, Roussel D, Matheus S, et al. Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe. Euro Surveill. 2014; 19.

7. Chow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, et al. Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis. 2011; 203: 149–57. https://doi.org/10.1093/infdis/jiq042 PMID: 21288619

8. Borgerini G, Poubaupe F, Jossaume A, Gouix A, Cotte L, Michault A, et al. Persistent arthralgia associated with chikungunya virus: a study of 88 adults on reunion island. Clin Infect Dis. 2008; 47: 469–75. https://doi.org/10.1086/590003 PMID: 18611153

9. Hoarau JJ, Jaffar-Bandjee MC, Krejbi Trottet P, Das T, Li-Pat-Yuen G, Dassa B, et al. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol. 2010; 184: 5914–27. https://doi.org/10.4049/jimmunol.0900255 PMID: 20404278

10. Suhrbier A, Jaffar-Bandjee MC, Gasque P. Arthritogenic alphaviruses—an overview. Nat Rev Rheumatol. 2012; 8: 420–9. https://doi.org/10.1038/nrrheum.2012.64 PMID: 22565316

11. Ganu MA, Ganu AS. Post-chikungunya chronic arthritis—our experience with DMARDs over two year follow up. J Assoc Physicians India. 2011; 59: 83–6. PMID: 21751641

12. Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P, et al. Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. Medicine (Baltimore). 2007; 86: 123–37.

13. Sissoko D, Malvy D, Ezzedine K, Renault P, Moscetti F, Ledrans M, et al. Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl Trop Dis. 2009; 3: e389.
14. Schilte C, Staikowsky C, Couderc T, Madec Y, Carpentier F, Kassab S, et al. Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis. 2013; 7: e2137.

15. Moro ML, Grilli E, Corveta A, Silvi G, Angelini R, Mascella F, et al. Long-term chikungunya infection clinical manifestations after an outbreak in Italy: a prognostic cohort study. J Infect. 2012; 65: 165–72. https://doi.org/10.1016/j.jinf.2012.04.005 PMID: 22522292

16. Couturier E, Guillemin F, Mura M, Leon L, Virion JM, Letort MJ, et al. Impaired quality of life after chikungunya virus infection: a 2-year follow-up study. Rheumatology (Oxford). 2012; 51: 1315–22.

17. Teo TH, Lum FM, Claser C, Lulla V, Lulla A, Merits A, et al. A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice. J Immunol. 2013; 190:259–69. https://doi.org/10.4049/jimmunol.1202177 PMID: 23209328

18. Ruiz Silva M, van der Ende-Metselaar H, Mulder HL, Smit JM, Rodenhuis-Zybert IA. Mechanism and role of MCP-1 upregulation upon chikungunya virus infection in human peripheral blood mononuclear cells. Sci Rep. 2016; 6:32288. https://doi.org/10.1038/srep32288 PMID: 27558873

19. Heeg M, Thimme R. Natural killer cells and hepatitis C: natural killer p46 expression linked to antiviral and antifibrotic activity. Hepatology. 2012; 56:1197–200. https://doi.org/10.1002/hep.25858 PMID: 22610395

20. Jiang Y, Cui X, Cui C, Zhang J, Zhou F, Zhang Z et al. The function of CD3+CD56+ NKT-like cells in HIV-infected individuals. Biomed Res Int. 2014; 2014:863625. https://doi.org/10.1155/2014/863625 PMID: 24779018

21. Watzl C, Long EO. Signal transduction during activation and inhibition of natural killer cells. Curr Protoc Immunol. 2010;Chapter 11: Unit 11 9B.

22. Das R, Tripathy A. Increased expressions of NKp44, NKp46 on NK/NKT-like cells are associated with impaired cytolytic function in self-limiting hepatitis E infection. Med Microbiol Immunol. 2014; 203: 303–14. https://doi.org/10.1007/s00430-014-0338-1 PMID: 24824867

23. Braud VM, Aldemir H, Breart B, Ferlin WG. Expression of CD94-NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells. Trends Immunol. 2003; 24: 162–4. PMID: 12697440

24. Moser JM, Gibbs J, Jensen PE, Lukacher AE. CD94-NKG2A receptors regulate antiviral CD8(+) T cell responses. Nat Immunol. 2002; 3: 189–95. https://doi.org/10.1038/ni757 PMID: 11812997

25. Conroy MJ, Mac Nicholas R, Grealy R, Taylor M, Otegbayo JA, O’Dea S et al. Circulating CD56dim natural killer cells and CD56+ T cells that produce interferon-γ or interleukin-10 are expanded in asymptomatic, E antigen-negative patients with persistent hepatitis B virus infection. J Viral Hepat. 2015; 22:335–45. https://doi.org/10.1111/jvh.12299 PMID: 25186004

26. Poo YS, Rudd PA, Gardner J, Wilson JA, Larcher T, Colle MA, et al. Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Negl Trop Dis. 2014; 8: e3354.

27. Singh VK, Damewood GPT, Friedman RM, Maheshwari RK. Tunicamycin enhances virus replication and inhibits antiviral activity of interferon in mice: correlation with natural killer cells. J Exp Pathol. 1987; 3: 19–33.

28. Smee DF, Alaghamandpan HA, Jin A, Sharma BS, Jolley WB. Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice. Antiviral Res. 1990; 13: 91–102. PMID: 1693058

29. Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, et al. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J Virol. 2013; 87: 13878–88. https://doi.org/10.1128/JVI.02666-13 PMID: 24131709

30. Thanapat S, Das R, Tripathy AS. Phenotypic and functional analyses of NK and NKT-like populations during the early stages of chikungunya infection. Front Microbiol. 2015; 6: 895. https://doi.org/10.3389/fmicb.2015.00895 PMID: 26388848

31. Petitdemange C, Becquart P, Wauquier N, Béziat V, Debré P, Leroy EM, et al. Unconventional repertoire profile is imprinted during acute chikungunya infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog. 2011; 7:e1002268.

32. Petitdemange C, Wauquier N, Devilliers H, Yssel H, Mombo I, Caron M, et al. Longitudinal Analysis of Natural Killer Cells in Dengue Virus-Infected Patients in Comparison to Chikungunya and Chikungunya/Dengue Virus-Infected Patients. PLoS Negl Trop Dis. 2016; 10:e0004499.

33. Thanapat S, Ganu M, Giri P, Kuikami S, Sharma M, Babar P, et al. Impaired NK cell functionality and increased TNF-alpha production as biomarkers of chronic chikungunya arthritis and rheumatoid arthritis. Hum Immunol. 2017; 78:370–374. https://doi.org/10.1016/j.humimm.2017.02.006 PMID: 28213049
34. Tripathy AS, Das R, Chadha MS, Arankalle VA. Epidemic of hepatitis B with high mortality in India: association of fulminant disease with lack of CCL4 and natural killer T cells. J Viral Hepat. 2011; 18: e415–22. https://doi.org/10.1111/j.1365-2893.2011.01457.x PMID: 21914058

35. Fu GF, Chen X, Hao S, Zhao JL, Hu HY, Yang HT, et al. Differences in natural killer cell quantification and receptor profile expression in HIV-1 infected Chinese children. Cell Immunol. 2010; 265: 37–43. https://doi.org/10.1016/j.cellimm.2010.06.011 PMID: 20678758

36. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004; 294: 15–22. https://doi.org/10.1016/j.jim.2004.08.006 PMID: 15604012

37. Kumar M, Sudeep AB, Arankalle VA. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine. 2012; 30: 6142–9. https://doi.org/10.1016/j.vaccine.2012.07.072 PMID: 22884660

38. Moretta L, Romagnani C, Pietra G, Moretta A, Mingari MC. NK-CTLs, a novel HLA-E-restricted T-cell subset. Trends Immunol. 2003; 24: 136–43. PMID: 12615209

39. De Maria A, Fogli M, Costa P, Murdaca G, Puppo F, Mavilio D, et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol. 2003; 33: 2410–8. https://doi.org/10.1002/eji.200324141 PMID: 12938217

40. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001; 19: 197–223. https://doi.org/10.1146/annurev.immunol.19.1.197 PMID: 11244035

41. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999; 17: 189–220. https://doi.org/10.1146/annurev.immunol.17.1.189 PMID: 10358757

42. Suhrbier A, Mahalingam S. The immunobiology of viral arthritides. PharmacolTher. 2009; 124: 301–8.

43. Lidbury BA, Rulli NE, Suhrbier A, Smith PN, McColl SR, Cunningham AL, et al. Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthropenic alphavirus. J Infect Dis. 2008; 197: 1585–93. https://doi.org/10.1086/587841 PMID: 18433328

44. Brandstadtter JD, Yang Y. Natural killer cell responses to viral infection. J Innate Immun. 2011; 3: 274–9. https://doi.org/10.1159/000324176 PMID: 21419795

45. Alsharifi M, Lobigs M, Simon MM, Kersten A, Muller K, Koskinen A, et al. NK cell-mediated immunopathology during an acute viral infection of the CNS. Eur J Immunol. 2006; 36: 887–96. https://doi.org/10.1002/eji.200535342 PMID: 16541469

46. Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, et al. Chikungunya virus arthritis in adult wild-type mice. J Virol. 2010; 84: 8021–32. https://doi.org/10.1128/JVI.02603-09 PMID: 20519386

47. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994; 369: 31–7. https://doi.org/10.1038/369031a0 PMID: 8164737